See analyst estimates and all valuation multiples for Vaccines & Immunotherapies
| Company | EV | EV/LTM Revenue | EV/LTM EBITDA |
|---|---|---|---|
| $234B | 3.6x | 8.1x | |
| $183B | 2.9x | 7.4x | |
| $123B | 2.3x | 7.9x | |
| $101B | 2.3x | 7.0x | |
| $75.3B | 4.8x | 14.2x | |
| $47.7B | 6.0x | 20.8x | |
| $10.2B | n/a | n/a | |
| $9.1B | 3.9x | 44.3x | |
| $7.1B | 7.6x | 26.6x | |
| $7.1B | 2.7x | -4.9x | |
| $5.0B | 11.4x | 36.2x | |
| $4.8B | 2.0x | -1.2x | |
| $4.1B | 11.7x | 82.1x | |
| $3.9B | 5.9x | 15.3x | |
| $3.1B | 7.4x | 24.4x | |
| $2.8B | 34.8x | n/a | |
| $2.6B | 2.7x | 7.9x | |
| $2.6B | n/a | n/a | |
| $2.6B | 13.4x | -51.6x | |
| $2.5B | 6.6x | 25.6x | |
| $2.5B | n/a | n/a | |
| $2.5B | 6.8x | -42.0x | |
| $1.8B | 52.9x | -63.8x | |
| $1.6B | n/a | n/a | |
| $1.5B | 11.9x | 19.5x | |
| $1.4B | n/a | n/a | |
| $1.4B | 6.9x | 18.3x | |
| $1.3B | 7.7x | 26.0x | |
| $1.3B | 8.1x | 8.9x | |
| $1.2B | 3035.4x | n/a | |
| $1.1B | 6.0x | 20.4x | |
| $999M | 6.5x | 12.5x | |
| $996M | 222.6x | -4.3x | |
| $917M | 5.0x | n/a | |
| $913M | 3.9x | 12.5x | |
| $912M | 1.0x | 3.8x | |
| $846M | 14.3x | -6.6x | |
| $824M | 3.8x | -36.7x | |
| $781M | 3.3x | -48.1x | |
| $775M | 2.4x | 39.6x | |
| $608M | n/a | n/a | |
| $607M | 244.9x | -31.0x | |
| $582M | n/a | n/a | |
| $578M | n/a | -9.2x | |
| $565M | 7.0x | -23.3x | |
| $555M | 214.6x | -4.1x | |
| $538M | 63.9x | -2.3x | |
| $521M | 2002.0x | n/a | |
| $451M | n/a | n/a | |
| $443M | 2.1x | n/a | |
| $424M | 1.7x | -1.2x | |
| $404M | 3.8x | -4.5x | |
| $361M | 664.3x | n/a | |
| $360M | 18.3x | -1230.1x | |
| $352M | 2.0x | 8.4x | |
| $340M | 92.7x | n/a | |
| $290M | 330718.6x | -11.6x | |
| $283M | n/a | n/a | |
| $267M | 6.0x | -3.0x | |
| $263M | 1.3x | 6.5x | |
| $224M | 1.4x | n/a | |
| $197M | n/a | n/a | |
| $191M | 6.3x | -0.4x | |
| $186M | n/a | n/a | |
| $181M | n/a | n/a | |
| $179M | 1.7x | 7.8x | |
| $172M | n/a | n/a | |
| $171M | n/a | -4.8x | |
| $168M | 1.9x | -1.2x | |
| $164M | n/a | n/a | |
| $159M | 4.6x | -101.8x | |
| $156M | n/a | n/a | |
| $150M | n/a | n/a | |
| $146M | 2.2x | 6.3x | |
| $140M | n/a | n/a | |
| $138M | n/a | n/a | |
| $131M | n/a | n/a | |
| $126M | 12.9x | n/a | |
| $124M | 28.1x | -7.1x | |
| $123M | 51459.6x | -4.9x | |
| $120M | 50.4x | -0.4x | |
| $120M | n/a | -4.1x | |
| $117M | n/a | n/a | |
| $117M | n/a | -1.3x | |
| $105M | 8.2x | n/a | |
| $91.5M | 7.3x | n/a | |
| $89.6M | 705.5x | n/a | |
| $88.5M | 1.0x | 1006.9x | |
| $80.5M | 0.6x | 12.2x | |
| $79.2M | n/a | n/a | |
| $73.2M | n/a | n/a | |
| $71.4M | 17.7x | n/a | |
| $69.0M | n/a | n/a | |
| $58.0M | n/a | -2.6x | |
| $56.8M | 6233.0x | -0.2x | |
| $49.6M | 15.6x | -1.6x | |
| $49.2M | 684.7x | n/a | |
| $48.8M | n/a | n/a | |
| $44.5M | 26.0x | -0.7x | |
| $41.2M | n/a | -1.0x | |
| $39.6M | n/a | n/a | |
| $38.1M | n/a | n/a | |
| $37.8M | 3.1x | n/a | |
| $37.5M | 0.5x | -0.6x | |
| $37.1M | 4.7x | n/a | |
| $24.9M | 43.5x | n/a | |
| $22.8M | 42.6x | n/a | |
| $22.8M | n/a | n/a | |
| $20.5M | 522.6x | n/a | |
| $17.1M | n/a | n/a | |
| $16.4M | 6.8x | n/a | |
| $16.4M | 6.4x | n/a | |
| $16.1M | 560.1x | -0.1x | |
| $15.6M | 8.2x | -1.1x | |
| $15.3M | 2.6x | n/a | |
| $8.8M | n/a | n/a | |
| $6.5M | n/a | n/a | |
| $1.9M | 0.5x | -0.1x | |
| -$0.6M | -0.1x | n/a | |
| -$1.5M | n/a | 0.0x | |
| -$5.7M | n/a | n/a | |
| -$12.5M | n/a | 0.1x | |
| -$16.2M | n/a | n/a | |
| -$18.4M | -6.2x | 0.5x | |
| -$21.5M | -2.8x | 0.2x | |
| -$22.5M | -0.4x | 0.1x | |
| -$29.5M | -6.6x | n/a | |
| -$30.4M | -3.6x | 0.2x | |
| -$31.2M | n/a | n/a | |
| -$35.9M | n/a | 0.3x | |
| -$36.2M | n/a | 0.2x | |
| -$38.7M | -0.3x | n/a | |
| -$42.2M | n/a | n/a | |
| -$46.7M | -0.4x | 0.3x | |
| -$66.9M | -891.9x | n/a | |
| -$71.2M | n/a | n/a | |
| -$75.8M | -2.6x | n/a | |
| -$78.6M | n/a | n/a |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Vaccines & Immunotherapies